MCK Price Prediction Next Week
Analysis and Insights
To predict the stock price of McKesson Corporation (MCK) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
MCK's stock shows a bullish trend with key technical indicators signaling potential upside:
- RSI (14-period): 65.15, indicating the stock is in a neutral zone but approaching overbought territory.
- MACD: Positive at 14.21, with a rising histogram, suggesting continued upward momentum.
- Stochastic Oscillator: Overbought at 88.56 (StochK) and 90.65 (StochD), which may indicate a short-term pullback.
The stock is trading above its 20-day and 50-day moving averages, with the 20-day SMA at 644.32 and the 50-day SMA at 655.50, confirming the bullish trend.
News Sentiment and Fundamental Analysis:
- Strong Financial Performance: MCK has demonstrated robust revenue growth, driven by its role in COVID-19 response and expansion in specialty pharmaceuticals. The company's earnings have doubled, supported by strategic acquisitions and share repurchases.
- High Valuation Interest: The stock has an 88% rating using the P/B Growth Investor model, indicating strong interest based on its fundamentals and valuation.
Price Prediction and Recommendation:
Based on the technical indicators and strong fundamental backdrop, MCK is expected to reach $670 in the next trading week. The stock is a BUY on dips near the Fibonacci pivot level of 653.27.
MCK Similar Chart Price Prediction
The price of MCK is predicted to go up -1.98%, based on the high correlation periods with TSN. The similarity of these two price pattern on the periods is 98.3%.
MCK
TSN
Down: -1.98%Similarity: 98.3%
MCK Revenue Forecast
MCK EPS Forecast
MCK FAQs
What is MCK revenue forecast for next quarter？
What is MCK eps forecast for next quarter？
MCK VS S&P500
McKesson distributes pharmaceutical products to nearly one third of the industry, leading to substantial negotiation leverage with generic drug manufacturers.
Direct-to-store model (delivering drugs directly to each retailer's stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007), solidifying McKesson's role in the supply chain.
Technology advancements continue to improve McKesson's performance and present new opportunities for wholesalers.
MCK Analyst's Forecast
Stephen Baxter
Wells Fargo
Hold
2025-03-14
Price Target
$641 → $691
Upside
+6.24%
Wells Fargo raised the firm's price target on McKesson to $691 from $641 and keeps an Equal Weight rating on the shares. The firm's 2025 adjusted EPS is unchanged, but Wells is increasing forward estimates on modestly stronger Pharma growth and more credit for annualizing Medical cost cuts. The firm cites modestly higher multiple, modestly higher core estimates, and including PRISM for the target change.
Daniel Grosslight
Citigroup
Strong Buy
2025-01-10
Price Target
$713 → $677
Upside
+16.38%
Erin Wright
Morgan Stanley
Buy
2024-12-17
Price Target
$612 → $642
Upside
+14.08%
